Usefulluness of single inhalaer treatment with long acting muscarinic antagonist, long acting beta agosit, and inhaled corticosteroid in symptomatic patients with chronic obstructive pulmonary disease without asthma and exacerbation

Usefulluness of single inhalaer treatment with long acting muscarinic antagonist, long acting beta agosit, and inhaled corticosteroid in symptomatic patients with symptomatic chronic obstructive pulmonary disease without asthma and exacerbation - Triple therapy for symptomatic COPD without asthma and exacerbation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039915

Enrollment

Registered

2020-03-26

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

single inhaler with umeclidinium bromide, vilanterol trifenatate, and fulticasone furoate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptomatic COPD patients who are recieving single inhaler treatment with long acting beta agonist and long acting muscarinic antagonist and do not have asthma and exacerbation history

Exclusion criteria

Exclusion criteria: Asmptomatic COPD patients, asthma COPD overlap patients, COPD patients with exacerbation history, COPD patients with malignancy, COPD patients with other serious medical conditions, and COPD patients who were judged to be unsuitable for this study by attending physicians

Design outcomes

Primary

Measure	Time frame
Change in chronic COPD assesement test score and % forced expiratory capacity in 1 second before and 8 and 24 weeks after the initiation of triple therapy	—

Countries

Japan

Contacts

Public ContactMikio Toyoshima

Hamamtsu Rosai Hospital Department of Respiratory Medicine

mi-toyoshima@hamamatsuh.johas.go.jp0534621211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026